Skip to main content
. 2023 May 24;14:1200748. doi: 10.3389/fimmu.2023.1200748

Table 1.

Characteristics of 51 patients with r/r DLBCL prior to CAR-T therapy.

Group A (n=6) Group B (n=25) Group C (n=20) P value
Median age, years (range) 55.3 (44-66) 57.0 (34-72) 52.9 (33-72) 0.41
Age≥65years (n,%) 1 (16.7%) 6 (24%) 3 (15%) 0.74
Male gender (n,%) 5 (83.3%) 13 (52%) 11 (55%) 0.37
Stage III-IV at diagnosis (n,%) 6 (100%) 20 (80%) 17 (85%) 0.48
Median LDH at diagnosis, U/L (range) 240.1 (167-361) 299.9 (98-803) 302.3 (129-917) 0.74
Bone marrow involvement at diagnosis (n,%) 5 (83.3%) 1 (4%) 3 (15%) <0.001
Extra nodal or CNS involvement at diagnosis (n,%) 2 (33.3%) 12 (48%) 7 (35%) 0.62
Median number of lines prior to CAR-T (range) 3 (2-5) 3.3 (2-7) 3.1 (2-6) 0.59
Transformed DLBCL 1 (16.7%) 3 (12%) 1 (5%) 0.61
Previous ASCT 2 (33.3%) 5 (20%) 3 (14.3%) 0.61
Previous use of CD20 antibody (n,%) 5 (83.3%) 25 (100%) 18 (90%) 0.18
Primary refractory after first line of therapy (n,%) 3 (50%) 9 (36%) 4 (20%) 0.30

LDH for lactate dehydrogenase, CNS for central nervous system, CAR-T for chimeric antigen receptor T cell therapy, DLBCL for diffuse large B-cell lymphoma, ASCT for autologous stem cell transplantation